A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Jianping Zhang et al.|Neuro-Oncology|2018Cited by 83
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocolNicholas F. Brown, Paul Mulholland, Stasya Ng et al.|BMC Cancer|2020Cited by 51
ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF<sup>11</sup>C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGINGPaul Mulholland, Sarah P. Blagden, Matthew Williams et al.|Neuro-Oncology|2015Cited by 3